Sandoz introduced additional progress on its biosimilar pipeline, with the discharge of constructive outcomes of the denosumab built-in section I/III scientific trial.

The ROSALIA research confirmed the first endpoints, the proposed biosimilar denosumab match reference product, by way of pharmacokinetics, pharmacodynamics, efficacy,

Read more